Press for TearScience

TearScience®, Inc., a privately-held medical device company, today announced that its system for evaporative dry eye, which includes the LipiView® Ocular Surface Interferometer and LipiFlow® Thermal Pulsation System, increased in acceptance among eye care physicians as a new standard of care in dry eye this month. Unsolicited demand for more than 30 live, in-booth LipiFlow® treatments was met above the seven demonstrations originally scheduled for the ASCRS•ASOA held in Chicago from April 20-24, 2012. Added requests for personal experience with the LipiFlow® treatment was a clear indicator of the impact that the TearScience® commercial offering made when unveiled for the first time since the U.S. Food and Drug Administration’s clearance for treatment of Meibomian gland dysfunction (MGD) and evaporative dry eye.

Dealing with dry, irritated eyes is a constant battle for many, but thanks to a new device developed by a company in the Triangle, some people who have struggled to find effective treatments are finally seeing a light at the end of the tunnel.

Dealing with dry, irritated eyes is a constant battle for many, but thanks to a new device developed by a company in the Triangle, some people who have struggled to find effective treatments are finally seeing a light at the end of the tunnel.
The device, called Lipiflow, uses a combination of heat and gentle pulsations to clear out clogged tear glands, allowing them to produce healthy tear film and keep eyes moist. It was developed by TearScience, a company based in Morrisville.

The results of a randomized, controlled clinical study of a new treatment for Meibomian Gland Dysfunction (MGD) and evaporative dry eye disease, using the LipiFlow® Thermal Pulsation System, was reported in Cornea to provide sustained improvement, on average, in both signs and symptoms. Further, this study demonstrated the clinical utility, safety and effectiveness of LipiFlow® in adult patients with MGD and dry eye symptoms.